Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 42.11 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $28.700 million which beat the analyst consensus estimate of $16.550 million by 73.41 percent. This is a 288.94 percent increase over sales of $7.379 million the same period last year.